
Herceptin, also known as trastuzumab, is used as a medication for patients who suffer from cancer, which assists in controlling the growth and spread of cancer cells in the body. Herceptin biosimilars are essentially used to treat certain breast as well stomach cancers, and is also used in combination with other medicines for treatment. Herceptin biosimilars have gained traction recently as a preferred treatment method for cancers. This is attributed to the fact that Herceptin biosimilars act on the surface of the cancer cell by blocking the chemical signals that can stimulate uncontrolled growth. The major factors that fuel the growth of the market are escalating incidence of cancers globally, along with an increase in the incidence of breast cancers among women. In addition, the rising focus on the development of herceptin therapeutic biosimilars to treat HER2+ breast cancers supplement the market growth. However, stringent regulations regarding the approval of hereceptin biosimilars restrain the growth of the hereceptin biosimilars market. Moreover, the increasing focus of market players in the development of herceptin biosimilars will offer profitable opportunities for the growth of the market.